New drug ZE74-0282 targets rare blood cancers in early trial
NCT ID NCT07529951
First seen Apr 23, 2026 · Last updated May 01, 2026 · Updated 2 times
Summary
This early-stage trial tests an experimental drug, ZE74-0282, in about 60 adults with blood cancers like polycythemia vera or myelofibrosis caused by a JAK2 mutation. The main goals are to find the safest dose and check for side effects, while also seeing if the drug shows any signs of fighting the cancer. Participants will take the drug by mouth and have regular blood tests and check-ups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.